<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04078438</url>
  </required_header>
  <id_info>
    <org_study_id>YUH-14-0389-B4</org_study_id>
    <nct_id>NCT04078438</nct_id>
  </id_info>
  <brief_title>Neurofeedback In Treatment Resistant Depression</brief_title>
  <official_title>Neurofeedback Treatment on Depressive Symptoms and Functional Recovery in Treatment-resistant Patients With Major Depressive Disorder: an Open-label Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yeungnam University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yeungnam University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators evaluate the effects of neurofeedback as an augmentation treatment on
      depressive symptoms and functional recovery in patients with treatment-resistant depression
      (TRD).

      TRD patients are assigned to the neurofeedback augmentation group and the medication-only
      (treatment as usual, TAU) group. The neurofeedback augmentation group underwent combined
      therapy comprising medication and 12-24 sessions of neurofeedback training for 12 weeks. To
      assess the serum levels of brain-derived neurotrophic factor (BDNF) in both groups, a pre-
      and post-treatment blood samples are obtained. Patients are evaluated using the Hamilton
      Depression Rating Scale (HAM-D), Beck Depression Inventory (BDI), Clinical Global
      Impression-Severity (CGI-S), 5-level version of European Quality of Life Questionnaire
      5-Dimensional Classification (EQ-5D-5L), and Sheehan Disability Scale (SDS) at baseline, and
      at the 1-, 4-, and 12-week.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Major depressive disorder (MDD) is a severely disabling disorder resulting in the
      deterioration of daily function and lowering quality of life. The lifetime prevalence of
      depression is 10-15%, and the annual prevalence of MDD in the United States is approximately
      7%. The World Health Organization has reported that MDD is expected to be the top disease in
      terms of global burden by 2030. Fifty percent of patients with depressive disorder have a
      chronic disease course, and 20% of such patients have insufficient responses to treatment
      despite the use of antidepressant medication. In addition, although antidepressants have been
      shown to be effective, residual symptoms may continue by stopping the medication early due to
      inconvenient side effects of the medication. Sixty percent of patients with depressive
      disorder have poorer executive function. Patients with depressive disorder are continuously
      affected by deficits in social functioning, such as interpersonal relationships and job
      adaptation, even if some of their symptoms are improved by medication. Therefore, various
      additional treatments other than antidepressant treatment have been tried to improve residual
      depressive symptoms and the remission rate.

      Brain waves have been used to measure brain activity and previous studies have reported that
      different brain waves reflect different brain states, including moods. Neurofeedback is a
      type of electroencephalography (EEG) training that allows individuals to change the levels of
      particular types of brain waves displayed on a computer by operational conditioning. EEG
      studies showed that the neurofeedback is capable of generating long term changes in the
      spectral EEG topography, while neuroimaging studies represented the neuroplastic effects from
      neurofeedback treatment. Neurofeedback is an alternative approach that aims to help
      individuals alter brain activation without introducing electrical or magnetic activity, or
      pharmacological compounds into the brain, hence preventing the brain from becoming dependent
      on outside influences for better functioning. It is noninvasive method and there's no report
      of even minor side effects.

      Neurofeedback may be considered a new augmentation treatment for patients with
      treatment-resistant depression (TRD), even after the use of antidepressants. Some studies
      have reported improvements in both depressive symptoms and executive function following
      neurofeedback treatment. A recent article insisted that neurofeedback treatment for
      depression as having &quot;revealed promising effects in recent clinical trials&quot;. However, most
      such studies have been case reports or uncontrolled studies, and the mechanism underlying the
      treatment effects of neurofeedback are still unclear. In addition, there has been no study of
      neurofeedback on depressive symptoms and functional recovery in patients with TRD.

      Brain-derived neurotrophic factor (BDNF) acts on certain neurons of the central nervous
      system and the peripheral nervous system. It helps support the survival of existing neurons
      and encourages the growth and differentiation of new neurons and synapses. Previous studies
      have suggested the presence of an etiological link between the development of depression and
      BDNF. However, no studies have examined the association between neurofeedback and changes in
      BDNF level.

      The purpose of this pilot study was to evaluate the effects of neurofeedback as an
      augmentation treatment on depressive symptoms and functional recovery in patients with TRD.
      The investigators also aimed to identify the usefulness of BDNF as a biomarker for
      neurofeedback by examining changes in the BDNF level before vs. after treatment in the
      neurofeedback treatment and medication-only (treatment as usual, TAU) groups.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Because of researcher foreign training
  </why_stopped>
  <start_date type="Actual">June 27, 2014</start_date>
  <completion_date type="Actual">February 8, 2020</completion_date>
  <primary_completion_date type="Actual">December 27, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Hamilton Rating Scale for Depression [HAM-D] score at baselline and the 1-, 4-, and 12-week time points</measure>
    <time_frame>at baseline, and at the 1-, 4-, and 12-week time points.</time_frame>
    <description>The HAM-D is an observer rating scale and 1 of the most widely used measures of depressive disorder. This scale composed of 17 items, and it has been used to assess the therapeutic effect as well as the severity of depression. Total score is 52, where higher scores indicating more severe depression. Hamilton considered Total score of 8-13 mild range, 14-18 moderate, 18-22 severe, and 23 or higher very severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Beck Depression Inventory- II (BDI-II) scores at baselline and the 1-, 4-, and 12-week time points</measure>
    <time_frame>at baseline, and at the 1-, 4-, and 12-week time points.</time_frame>
    <description>The BDI is self-report scale designed to evaluate the presence and severity of depressive symptoms. It is consisted of 21 items including cognitive, emotional, motivative, and physical symptoms of depression. Each question is scored from 0 to 3 points, and the total score ranges from 0 to 63, indicating the higher the total scores, the more severe the depression. It is considered total score of 0-9 minimal range, 10-15 mild, 16-23 moderate, and 24-63 severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Sheehan Disability Scale (SDS) score at baselline and the 1-, 4-, and 12-week time points</measure>
    <time_frame>at baseline, and at the 1-, 4-, and 12-week time points.</time_frame>
    <description>The SDS is a self-report scale designed by Sheehan to assess the severity of functional impairment. This scale consists of 3 items, and each item is divided into 11 levels from 0 to 10 points. It is considered 0 point: none, 1-3 points: mild, 4-6 points: moderate, and 7-10 points: severe. Total score ranges from 0 to 30 and means that the higher the total scores, the more severe the functional impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Clinical Global Impression-Severity (CGI-S) at baselline and the 1-, 4-, and 12-week time points</measure>
    <time_frame>at baseline, and at the 1-, 4-, and 12-week time points.</time_frame>
    <description>The CGI-S is a single-item scale composed of 7 levels ranging from maximum score of 7 to normal state of 1. This scale is a measure by which the evaluator comprehensively assesses the severity of mental illness regardless of diagnosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparisons of serum brain-derived neurotrophic factor (BDNF) level between baseline and the 12-week time point among groups</measure>
    <time_frame>at baseline, and 12-week time points.</time_frame>
    <description>Brain-derived neurotrophic factor (BDNF) acts on certain neurons of the central nervous system and the peripheral nervous system. It helps support the survival of existing neurons and encourages the growth and differentiation of new neurons and synapses. Previous studies have suggested the presence of an etiological link between the development of depression and BDNF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type and number of adverse events</measure>
    <time_frame>through study completion, an average of 12 weeks</time_frame>
    <description>adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in valuation of 5 level version of European Quality of Life Questionnaire 5-Dimensional Classification (EQ-5D-5L) (converted tariff score)</measure>
    <time_frame>at baseline, and at the 1-, 4-, and 12-week time points.</time_frame>
    <description>The EQ-5D-5L was developed by the EuroQol Group, and is used to assess 5 dimensions: mobility, self care, usual activity, pain/discomfort, and anxiety/depression. Each dimension is consisted of 5 levels, so total 3125 health states can be evaluated. The valuation of EQ-5D-5L (converted tariff score) is an index score calculated by applying weight to each of the 5 EQ-5D-5L questionnaires to provide a comprehensive summary of health-related quality of life. The resulting set of tariff is widely used to calculate preferences for EQ-5D-5L health states. As EQ-5D-5L is translated according to the culture and situation of each country, EQ-5D-5L tariffs may differ at each country. The index score is valued from 0 to 1, and the higher scores indicate the higher quality of life for the patients. In this study, EQ-5D-5L tariffs (index values) were calculated according to the [The EQ-5D-5L valuation study in Korea.].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in response and remission rate of Hamilton Rating Scale for Depression [HAM-D] score</measure>
    <time_frame>at baseline, and at the 1-, 4-, and 12-week time points.</time_frame>
    <description>Remission was defined as achieving a HAM-D score below 7, and response was defined as a 50% or greater reduction in HAM-D score from baseline.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Depression</condition>
  <condition>Neurofeedback</condition>
  <arm_group>
    <arm_group_label>neurofeedback augmentation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The neurofeedback augmentation group was asked to participate in 12 weeks of combined therapy of medication and 12-24 sessions of neurofeedback training. The neurofeedback protocol was determined considering the patient's main symptoms. Patients in the neurofeedback augmentation group received sensorimotor rhythm (SMR) beta or beta training for 30 minutes, and then alpha/theta (A/T) training for 30 minutes in each session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>medication-only (treatment as usual, TAU) group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions instead of neurofeedback training sessions. These sessions included psychological assessment and supportive psychotherapy. The medication-only (treatment as usual, TAU) group maintained the same medication use as that before the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The healthy controls provided blood samples using the same procedure at baseline only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>neurofeedback augmentation</intervention_name>
    <description>Neurofeedback training was performed using a Neurocybernetics EEG Biofeedback system (Neurocybernetics Inc., Encino, CA, USA). The neurofeedback protocol was determined by the neurofeedback team, which included 3 psychiatrists, in consideration of the patient's main symptoms.
The neurofeedback augmentation group was asked to participate in 12 weeks of combined therapy of medication and 12-24 sessions of neurofeedback training. Patients in the neurofeedback augmentation group received sensorimotor rhythm (SMR) beta or beta training for 30 minutes, and then alpha/theta (A/T) training for 30 minutes in each session.
To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions. The medication-only (treatment as usual, TAU) group maintained the same medication use as that before the study.</description>
    <arm_group_label>neurofeedback augmentation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>treatment as usual</intervention_name>
    <description>The neurofeedback augmentation group and the medication-only group maintained the same medication use as that before the study.</description>
    <arm_group_label>medication-only (treatment as usual, TAU) group</arm_group_label>
    <arm_group_label>neurofeedback augmentation group</arm_group_label>
    <other_name>medication</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>psychotherapy placebo sessions</intervention_name>
    <description>To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions instead of neurofeedback training sessions. These sessions included psychological assessment and supportive psychotherapy.</description>
    <arm_group_label>medication-only (treatment as usual, TAU) group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagosis with MDD according to the DSM-IV-TR criteria for MDD, and especially
             treatment-resistant MDD (Hamilton Rating Scale for Depression [HAM-D] score â©¾14)
             despite adequate antidepressant therapy)

        Exclusion Criteria:

          -  Psychosis

          -  Bipolar disorder

          -  Brain injury

          -  Clinically diagnosed neurological disorder

          -  Convulsive disorder

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eun-Jin Cheon, M.D., Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Yeungnam University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 22, 2019</study_first_submitted>
  <study_first_submitted_qc>August 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yeungnam University Hospital</investigator_affiliation>
    <investigator_full_name>Eun-Jin Cheon</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Treatment-resistant depression</keyword>
  <keyword>Neurofeedback</keyword>
  <keyword>Functional recovery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

